How does emerging patent case law in the US and Europe affect precision medicine?
Nat Biotechnol
.
2019 Oct;37(10):1118-1125.
doi: 10.1038/s41587-019-0265-1.
Authors
Mateo Aboy
1
,
Kathleen Liddell
2
,
Cristina Crespo
2
,
I Glenn Cohen
3
,
Johnathon Liddicoat
2
,
Sara Gerke
3
,
Timo Minssen
4
Affiliations
1
Centre for Law, Medicine, and Life Sciences (LML), Faculty of Law, University of Cambridge, Cambridge, UK. ma608@cam.ac.uk.
2
Centre for Law, Medicine, and Life Sciences (LML), Faculty of Law, University of Cambridge, Cambridge, UK.
3
Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard University, Cambridge, MA, USA.
4
Center for Advanced Studies in Biomedical Innovation Law (CeBIL), University of Copenhagen, Copenhagen, Denmark.
PMID:
31578504
DOI:
10.1038/s41587-019-0265-1
No abstract available
MeSH terms
Algorithms
Artificial Intelligence
Biological Products
Biomarkers
Europe
Humans
Patents as Topic / legislation & jurisprudence*
Precision Medicine / trends*
United States
Substances
Biological Products
Biomarkers